



ASX Release

30 July 2018

ZELDA THERAPEUTICS LIMITED
ACN 103 782 378

Level 26
140 St Georges Terrace,
Perth Western Australia 6000
Tel: +61 8 6558 0886
Fax: +61 8 6316 3337
E: enquiries@zeldatherapeutics.com
W: www.zeldatherapeutics.com

Contacts

Dr Richard Hopkins
Managing Director
+61 405 656 868
rhopkins@zeldatherapeutics.com

Mr Harry Karelis
Executive Chairman
+61 413 056 328
hkarelis@zeldatherapeutics.com

Directors

Dr Richard Hopkins
Mr Harry Karelis
Dr Stewart Washer
Ms Mara Gordon
Mr Jason Peterson

Tickers:

Australia (ASX): ZLD
USA (OTC): ZLDAF

Ordinary Shares:
755,341,934

Options:
46,000,000

1,500,000 (\$0.04 – 6/2/2020)
*4,500,000 (\$0.04 – 6/2/2020)
*40,000,000 (\$0.03125 – 17/11/2021)
* subject to vesting conditions

JUNE 2018 QUARTERLY REPORT

- Significant developments on the paediatric brain cancer project with prestigious Telethon Kids Institute
- Initial results presented to National and International medical research conferences
- Appointment of new Managing Director to lead next phase of growth
- Continued progress on insomnia and autism clinical programmes

The Board of **Zelda Therapeutics Ltd (ASX: ZLD, Zelda or the Company)** is pleased to provide an operational update to accompany its Appendix 4C, released today, for the three-month period to 30 June 2018.

OPERATIONAL PROGRESS

Paediatric Brain Cancer

The Company provided an update on its research programme with the Telethon Kids Institute. The research is focused on pre-clinical testing of Zelda's compounds to act as anti-cancer agents on the Institute's validated cell and animal models in a variety of brain cancers.

Initial results showed pure cannabinoids (THC and CBD) had an anti-cancer effect on brain cancer cells. Further increases in cell killing activity were achieved when THC and CBD were combined with cyclophosphamide, a front line chemotherapy drug. These results were presented at the inaugural Australian Society of Medical Research and International Cannabinoid Research Society conferences.

Insomnia Trial

Patient recruitment was completed for Zelda's pioneering insomnia trial, which is being undertaken at the prestigious University of Western Australia Centre for Sleep Science. Patient recruitment has been completed and dosing is on-track to commence shortly. Preliminary results are expected within six months of commencement.

Autism Observational Trial

Zelda was pleased to announce that its autism observational trial, which is being conducted at the USA-based Children's Hospital of Philadelphia (CHOP), received Institutional Review Board (IRB) approval. This is the equivalent to Human Research Ethics Approval in Australia and essentially allows the planned study to commence within the parameters of the approved trial protocols.

This study will lay the groundwork for a possible future clinical trial with preliminary results expected within six months.

Appointment of New Managing Director

The Company announced the appointment of Dr Richard Hopkins as Managing Director, commencing subsequent to the end of the quarter on 16 July 2018. Dr Stewart Washer reverted to a non-executive position.

Corporate

The Company has been focused on making significant progress across all clinical and pre-clinical research fronts and laying the foundations for upcoming research activities.

As Zelda continues to grow and expand its activities, it remains focused on generating shareholder value through identifying and securing new intellectual property and determining the fastest way to market, for its medicinal cannabis products.

The Company closed the quarter with a cash position of \$5.69 million.

Dr Richard Hopkins, Managing Director stated: *“I’m delighted to have formally joined the Zelda team, which is poised to deliver on a number of clinical and commercial endpoints. We’ve seen in the previous quarter that Zelda has made significant progress with its pre-clinical and clinical activities. I am excited to continue to build on the foundations established by Harry and the Zelda team.”*

Harry Karelis, Executive Chairman said *“Zelda continues to develop and strengthen its position as a leading research-based medicinal cannabis company. This quarter we have continued to make solid progress as we continue with our various initiatives. I am also delighted to welcome our new Managing Director, Dr Richard Hopkins to the team. I am confident that Richard’s broad and in-depth knowledge of drug development, intellectual property and the pharmaceutical industry will add value to our overall strategy and accelerate delivery of our research programmes”*

Tim Slate

Company Secretary

About Zelda Therapeutics (www.zeldatherapeutics.com)

Zelda Therapeutics Ltd (“Zelda”) is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising:

- A **human clinical trial programme** focused on insomnia, autism and eczema with activities in Australia, Chile and the USA.
- A **pre-clinical research programme** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

It has partnered with the world’s leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer and cognitive decline.